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We present data obtained using a focused proteomics approach to
identify the glycosylphosphatidylinositol (GPI)-anchored peptides in
19 human cancer cell lines. GPI-anchored proteins (GPI-APs), which
localize to the outer leaﬂet of the membranemicrodomains commonly
referred to as lipid rafts play important roles in diverse biological
processes. Due to the complex structure of the GPI-anchor moiety, it
has been difﬁcult to identify GPI-anchored peptide sequences on the
proteomic scale by database searches using tools such as MASCOT.
Here we provide data from 73 ω-sites derived from 49 GPI-APs in 19
human cancer cell lines. This article contains data related to the
research article entitled “Identiﬁcation of glycosylphosphatidylinositol-
anchored proteins and ω-sites using TiO2-based afﬁnity puriﬁcation
followed by hydrogen ﬂuoride treatment” (Masuishi et al., 2016) [1].
& 2016 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Biology
ore speciﬁc sub-
ject areaProteomics, Post-translational modiﬁcationvier Inc. This is an open access article under the CC BY license
/j.jprot.2016.03.008
search Center, Yokohama City University, Fukuura 3-9, 8 Kanazawa, Yoko-
Hirano).
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ow data was
acquiredMS data were acquired using data-dependent acquisition mode on a LTQ
Orbitrap Velos mass spectrometer (Thermo Fisher Scientiﬁc).ata format Raw, Analyzed
xperimental
factorsDigested GPI-anchored peptides were treated with hydrogen ﬂuoride.xperimental
featuresGPI-anchored proteins were isolated from human cancer cell lines using
Triton X-114 phase separation and PI-PLC treatment. The digested peptides
were analyzed by nano-LC-MS/MS.ata source
locationFukuura 3-9, 8 Kanazawa, Yokohama 236-0004, Japanata accessibility Data is within this article and have been deposited in the ProteomeXchange
Consortium (http://proteomecentral.proteomexchange.org) via the PRIDE
partner repository with the dataset identiﬁer PRIDE: PXD003105.Value of the data
 Identiﬁcation of novel GPI-APs and ω-sites.
 These data provide the ﬁrst evidence that the GPI-anchor attaches to multiple amino acids in the C-
terminal site, yielding a variety of protein species.
 These data may be helpful in understanding the mechanisms of GPI anchoring.1. Data
We present 46 RAW mass spectrometry data ﬁles with negative controls that correspond to our
LC-MS/MS analysis of 19 human cancer cell lines (ovarian cancer cell lines OVISE, A2780, OVCAR-3,
OVMANA, OVSAHO, and OVSAYO, renal cancer cell lines 786-O, A498, ACHN, Caki-1, Caki-2 and
UMRC3, bladder cancer cell lines 5637, T24 and UMUC3, prostate cancer cell lines DU145, LNCaP and
PC3, and neuroblastoma cell line SH-SY5Y).
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium
via the PRIDE partner repository [2] with the dataset identiﬁer PRIDE: PXD003105.2. Experimental design, materials and methods
The detailed method is described elsewhere [1].
2.1. Isolation of GPI-Aps
This procedure was performed as previously described [3]. The GPI-AP–enriched fraction, termed
the detergent-resistant membrane (DRM) fraction, was puriﬁed by sucrose gradient fractionation. The
DRM fraction was resuspended in 50 mM HEPES [pH 7.5] and 1% (v/v) Triton X-114. This solution was
subjected to Triton X-114 two-phase separation with or without Phosphatidylinositol-speciﬁc phos-
pholipase C (PI-PLC) (from Bacillus cereus; Molecular-Probes USA) treatment. Supernatants were
concentrated by trichloroacetic acid (TCA)/acetone precipitation and subjected to in-solution diges-
tion (digestion with either trypsin, chymotrypsin).
2.2. GPI-APs digestion
For in-solution digestion, PI-PLC treated GPI-APs were resuspended in 20 ml of 8 M urea, and
dithiothreitol (DTT) was added to a ﬁnal concentration of 10 mM. This mixture was incubated for
30 min at 37 °C, chilled, brought to a ﬁnal concentration of 10 mM iodoacetic acid for S-alkylation,
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diluted with 3 volumes of 50 mM NH4HCO3 at a ﬁnal concentration of 2 M urea. Proteins were
digested with 0.1 mg trypsin (Trypsin Gold, MS Grade; Promega, USA) or 0.1 mg chymotrypsin (Chy-
motrypsin Sequencing Grade; Roche Applied Science, USA), and the sample was incubated at 37 °C for
18 h. To stop the digestion, 1 ml of 20% triﬂuoroacetic acid (TFA) (Wako, Japan) was added to the
sample. The peptide fragments were desalted using StageTips [4] with C18 Empore disk membranes
(3M Company, USA) and SDB (3M Company), and then eluted with 200 ml of 60% (v/v) acetonitrile/
0.1% (v/v) TFA. The eluates were immediately dried under vacuum and dissolved in 0.1% TFA.
2.3. GPI-anchored peptide enrichment and aqueous hydrogen ﬂuoride (HF) treatment
The GPI-anchored peptide enrichment procedure was carried out using the Titansphere Phos-TiO
Kit (GL Sciences, Japan) according to the manufacturer's instructions. Bound GPI-anchored peptides
were eluted with 50 ml of 5% NH3–H2O. Eluates were immediately dried under vacuum, and then
treated with or without 20 ml of 50% (v/v) aqueous hydrogen ﬂuoride (HF) (Wako, Japan) for 12 h at
4 °C to cleave the ethanolamine–phosphate bond. The peptide samples were again completely dried
under vacuum, and then dissolved in 0.1% TFA for LC–MS/MS analysis. The negative control PI-PLC(-)
or HF(-) samples from OVISE cell and SH-SY5Y cell are shown in Table S1.
2.4. Nano-LC and LTQ orbitrap velos setup
Prior to injection into the mass spectrometer, The peptide samples were loaded in a reverse-phase
precolumn (C18 PepMap column, LC Packings, USA) and resolved on a nanoscale C18 PepMap
capillary column (75 mm id15 cm, LC Packings, USA) at a ﬂow rate of 300 nl/min with a gradient of
acetonitrile/0.1% (v/v) formic acid. The mobile phases were solvent A (0.1% formic acid/2% (v/v)
acetonitrile) and B (95% acetonitrile, 5% water, 0.1% formic acid). Peptides were separated using a
linear gradient from 5% to 40% solvent B for 30 min. The full-scan mass spectra were measured from
m/z 350–1200 in positive-ion electrospray ionization mode on a LTQ Orbitrap Velos mass spectro-
meter (Thermo Fisher Scientiﬁc, USA) operated in data-dependent mode and subjected to CID frag-
mentation using the TOP15 strategy. In brief, a scan cycle was initiated with a full scan of high mass
accuracy in the Orbitrap, followed by MS/MS scans of the ﬁfteen most intense precursor ions in the
linear ion trap, with dynamic exclusion of previously selected ions. The other parameter settings were
as follows: normalized collision energy, 35%; electrospray voltage, 1.8 kV; capillary temperature,
250 °C, and isolation width, 2 (m/z).
2.5. Data analysis
The raw MS spectrum was processed using Proteome Discoverer (v.1.3.0.339, Thermo Fisher Sci-
entiﬁc), applying Mascot (v.2.4.0, Matrix Science) for peptide identiﬁcation. The data were queried
against UniProt/SWISS-PROT database (v2012-0711; Homo sapiens 20,232 sequences). All database
searches were performed using a precursor mass tolerance of 75 ppm, fragment ion mass tolerance
of 70.5 Da, enzyme name set to semi-speciﬁc trypsin or semi-speciﬁc chymotrypsin, and a max-
imum missed-cleavages value of 2. Oxidation of Met were set as variable modiﬁcations. Fixed
modiﬁcations were set to carboxymethyl of Cys. To identify GPI-anchored peptide sequences, the EtN
moiety (þ43.0422 Da) was set as a variable modiﬁcations of the C-terminal peptide. As a control,
carbamylation of Lys, Arg, Cys., and the N-terminus were used as variable modiﬁcations (Table S2).
GPI-anchored peptide identiﬁcation was considered positive when a match yielded one peptide with
an ion score greater than 30 and the false-discovery rate was ﬁxed to a threshold of 0.01 at peptide
level. Table S1 provides a detailed list of all identiﬁed GPI-anchored peptides from 19 human cancer
cell lines along with the following additional information: accession number, gene name, enzyme
used, identiﬁed peptide sequence, ion score, and molecular mass. The MS/MS spectra derived from 73
GPI-anchored peptides (EtN modiﬁed peptides) are shown in Figure S1. A detailed list of all GPI-
anchored peptides identiﬁed using an FDR of 0.05 is provided in Table S3. The mass spectrometry
proteomics data have been deposited to the ProteomeXchange Consortium (http://proteomecentral.
Y. Masuishi et al. / Data in Brief 7 (2016) 1302–1305 1305proteomexchange.org) via the PRIDE partner repository [2] with the dataset identiﬁer PRIDE:
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